# Allergy Therapeutics plc Jeff Barton brings extensive commercial experience to the board

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-jeff-barton-brings-extensive-commercial-experience-board/412723378
- Published: 2017-02-08T07:24:16+00:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical company specialising in allergy vaccines,
announces the appointment of Mr Jeff Barton to the Company’s Board as a Non-Executive
Director, nominated by **Abbott Laboratories, Inc.** (NYSE:ABT) in replacement of
Mr Jean-Yves Pavee who retires from the Board, both effective after close of business
7 February 2017.

Jeff Barton currently serves as Vice President, Licensing and Acquisitions, at Abbott.
During his time in this role, Abbott has executed several strategically important
transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals 
and Veropharm. He has served Abbott since joining in 1990 in the Financial Development
Training program, and during his career has held a variety of financial management
positions across Abbott’s businesses, including in Diagnostics, Nutrition and Pharmaceuticals.
He previously served as Divisional Vice President and Controller for Abbott’s North
American Nutrition Business and as Area Finance Director for its Asian, African,
and Middle Eastern Pharmaceutical unit. Mr Barton holds a degree in accounting from
Indiana University, and a Masters of Management from the Northwestern University
Kellogg Graduate School of Management.

> **Peter Jensen, Chairman of Allergy Therapeutics plc, commented:** “We are pleased
> to welcome Jeff to the Board. He brings extensive commercial experience, particularly
> in the United States, which will be valuable to our Company as we continue to 
> execute our global strategy. We also wish to take this opportunity to thank Jean-
> Yves for his contribution and support to Allergy Therapeutics since 2014.”

Jeffery Glen Barton, age 48, has no current or prior directorships in the past five
years. Allergy Therapeutics confirms that there are no further disclosures to be
made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for
Companies.

Share on:
